Static Model-Based Assessment of OATP1B1-Mediated Drug Interactions with Preincubation-Dependent Inhibitors Based on Inactivation and Recovery Kinetics

被引:7
|
作者
Taguchi, Takayuki [1 ,2 ]
Masuo, Yusuke [2 ]
Futatsugi, Azusa [2 ]
Kato, Yukio [2 ]
机构
[1] Kaken Pharmaceut Co Ltd, Pharmacokinet & Safety Dept, Drug Res Ctr, Kyoto, Japan
[2] Kanazawa Univ, Fac Pharm, Inst Med Pharmaceut & Hlth Sci, Kakumamachi, Kanazawa, Ishikawa 9201102, Japan
关键词
HEPATIC-UPTAKE; PREDICTION; OATP; PHARMACOKINETICS; TRANSPORTER; IMPACT; IRINOTECAN; PROFILES;
D O I
10.1124/dmd.120.000020
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Quantitative assessment of drug-drug interactions (DDIs) via organic anion transporting polypeptide (OATP) 1B1 is one of the key issues in drug development. Although OATP1B1 inhibition exhibits unique characteristics, including preincubation dependence for some inhibitors, a limited approach has been attempted based on the static model that considers such preincubation dependence in the prediction of DDIs via OATP1B1. The present study aimed to establish the prediction of DDIs via OATP1B1 using preincubation-dependent inhibitors based on the static model and incorporating both inactivation and recovery of OATP1B1 activity. Cyclosporine A was selected as a preincubation-dependent inhibitor, as well as five substrates that include probes and pharmaceuticals. The inhibition ratio (R value) calculated on the basis of a conventional static model, considering inhibition of OATP1B1 and contribution ratio of OATP1B1 to the overall hepatic uptake, was much lower than the reported AUC ratio, even when IC50 values were estimated after preincubation conditions. Conversely, the R value that was estimated by considering inactivation and recovery parameters was closer to the AUC ratio. The R value that was calculated assuming the complete contribution of OATP1B1 was much higher than the AUC ratio, avoiding false-negative prediction. The R value estimated by considering inactivation and recovery for another combination of a preincubation-dependent inhibitor, asunaprevir, and substrate drug, rosuvastatin, was also closer to the AUC ratio. Thus, R values calculated based on such OATP1B1 kinetics would be potential alternative indexes for the quantitative prediction of OATP1B1-mediated DDIs using preincubation-dependent inhibitors, although this prediction is affected by estimation of the contribution ratio of substrates. SIGNIFICANCE STATEMENT Static model-based quantitative prediction of organic anion transporting polypeptide 1B1-mediated drug-drug interactions induced by preincubation-dependent inhibitors was newly proposed to avoid false-negative prediction.
引用
收藏
页码:750 / 758
页数:9
相关论文
共 38 条
  • [21] REDUCED PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL FOR REPAGLINIDE: IMPACT OF OATP1B1 GENOTYPE AND SOURCE OF IN VITRO DATA ON THE PREDICTION OF DRUG-DRUG INTERACTION RISK
    Gertz, Michael
    Saell, Carolina
    Houston, J. Brian
    Galetin, Aleksandra
    DRUG METABOLISM REVIEWS, 2014, 45 : 258 - 258
  • [22] A NEW CELL-BASED MODEL TO STUDY THE IMPORTANT MATTERS OF OATP1B ON DRUG DISPOSITION: GENETIC VARIANTS AND SPECIES DIFFERENCES
    Li, Na
    Wang, Jie
    Cooper, Kirsten
    Bourgea, Joanne
    Singh, Ritu
    Creegan, Tim
    Crespi, Charles L.
    Patten, Christopher J.
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S106 - S106
  • [23] Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug–Drug–Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole
    Denise Türk
    Nina Hanke
    Sarah Wolf
    Sebastian Frechen
    Thomas Eissing
    Thomas Wendl
    Matthias Schwab
    Thorsten Lehr
    Clinical Pharmacokinetics, 2019, 58 : 1595 - 1607
  • [24] Inhibitory Effects of Alkaloids on OATP1B1 In Vitro and In Vivo: Prediction for Food/Herb-Drug Interactions and Hepatoprotective Effects Based on Structure-Activity Relationships
    Sun, Yanhong
    Tan, Huixin
    Wang, Fenghe
    Hu, Jiahuan
    Duan, Xiaoyan
    Bai, Wanting
    Wu, Jinjin
    Bai, Jie
    Hu, Jinping
    CHEMICAL RESEARCH IN TOXICOLOGY, 2025, 38 (02) : 281 - 295
  • [25] Unusual Distribution Kinetics of Gadoxetate in Healthy Human Subjects Genotyped for OATP1B1: Application of Population Analysis and a Minimal Physiological-Based Pharmacokinetic Model
    Weiss, Michael
    Siegmund, Werner
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (04): : 506 - 514
  • [26] Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole
    Tuerk, Denise
    Hanke, Nina
    Wolf, Sarah
    Frechen, Sebastian
    Eissing, Thomas
    Wendl, Thomas
    Schwab, Matthias
    Lehr, Thorsten
    CLINICAL PHARMACOKINETICS, 2019, 58 (12) : 1595 - 1607
  • [27] Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors
    Richard A. J. Darby
    Amanda Unsworth
    Stefan Knapp
    Ian D. Kerr
    Richard Callaghan
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 853 - 864
  • [28] Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors
    Darby, Richard A. J.
    Unsworth, Amanda
    Knapp, Stefan
    Kerr, Ian D.
    Callaghan, Richard
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 853 - 864
  • [29] Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk
    Gertz, Michael
    Tsamandouras, Nikolaos
    Saell, Carolina
    Houston, J. Brian
    Galetin, Aleksandra
    PHARMACEUTICAL RESEARCH, 2014, 31 (09) : 2367 - 2382
  • [30] Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk
    Michael Gertz
    Nikolaos Tsamandouras
    Carolina Säll
    J. Brian Houston
    Aleksandra Galetin
    Pharmaceutical Research, 2014, 31 : 2367 - 2382